freephone 0800 862 0373
Sign in to view your quotes
Email address:
Password or PIN:

Forgotten your password? Reset it here.

New lung cancer drug turned down by NICE for use on the NHS

Published on 27/03/2013

A new drug for a rare form of lung cancer has been turned down for use on the NHS, but could be available for patients with private medical insurance.

A new drug has been turned down for use on the NHS

New drug crizotinib, marketed as Xalkori, is designed to treat non-small cell lung cancer that has spread to other parts of the body, and is caused by a particular gene defect.

For three-quarters of all new cases of this type of lung cancer, five-year survival rates are as low as five per cent because the cancer is advanced.

But new drug crizotinib is twice as effective as chemotherapy at halting the progression of the disease.

In clinical trials last year, the drug doubled the time taken for treated tumours to start growing again or stop shrinking.

Patients taking crizotinib had a progression-free survival of 7.7 months, compared with three months for those on standard chemotherapy.

The drug is licensed for private prescription in the UK, with a price tag of £4,000 a month. Patients can access it through their medical insurance or meet the costs themselves.

However, the National Institute for Health and Clinical Excellence (NICE) has turned down crizotinib for use on the NHS, because it does not consider it to be cost effective.

NICE normally recommends drugs costing around £20,000 per quality-adjusted life year (QALY). The cost for crizotinib when combined with chemo would be between £63,000 and £181,000.

Experts are disappointed at the decision, since the drug could potentially benefit 1,000 patients a year who otherwise would have very limited options.

Dr Michael Peake, clinical lead at the National Cancer Intelligence Network and National Cancer Lead at NHS Cancer Improvement, said:

"In an aggressive disease like advanced lung cancer, where, for the majority of patients, survival is exceptionally poor and where not all patients can expect to gain much benefit with existing therapies, there is an urgent need for new medicines like crizotinib which target the specific drivers of a patient's tumour.”

Because the drug is licensed for use in the UK, it may be covered by private medical insurers like Bupa and Aviva despite not being available on the NHS. For access to drugs like crizotinib in the future, look for a policy with full cancer cover.

© ActiveQuote Ltd. 2013

Categories:  MedicalNHS and Hospitals
New lung cancer drug turned down by NICE for use on the NHSA new drug for a rare form of lung cancer has been turned down for use on the NHS, but could be available for patients with private medical     tweet it on twittershare with your friends on Facebookshare with your friends on MySpaceBlog it on your LinkedIn profile

No.1 health insurance broker as rated by customers

Excellent service. Explained everything in detail and really helped to find the right insurance best suited to my needs - which wasn't necessarily the most expensive. 

Review centre member

Good value and the advisor was very helpful and recommended the best policy for my grandson. I would definitely use this service again and recommend to others.

Review centre member

We were contacted in good time to make a knowledgable choice. We were given plenty of options with lots of information to enable us to make the right choice.

Review centre member

The service I received was excellent, the staff member was very efficient and knowledgable. She went out of her way to get the best policy for me.

Review centre member

Great service. I really appreciated the help provided by Active Quote to arrange health insurance. The agent was very informative and proactive. Many thanks!

Review centre member

I received excellent care and attention from the first phone call till the last. Friendly, efficient and patient.

Review centre member

Staff are very helpful, friendly and polite. They call back when they say they will and keep you up to date with progress. Pleasure to deal with.

Review centre member

Very polite and friendly, and gave detailed explanations of all aspects of the cover. Reassuring to know that if you do have a problem there is someone you can contact.

Review centre member

Friendly and efficient. Nothing was too much trouble even when i needed to make a small change, excellent service.

Review centre member

The advisor was incredibly helpful and fully explained the differences between the policies. I really liked the fact that I was put under no pressure.

Review centre member
This site is operated by Insurance Broker ActiveQuote Ltd registered in England & Wales company number 6765845.
Authorised and Regulated by the Financial Conduct Authority (FCA). Firm reference number 501109 as detailed on the Financial Services Register. Please read our Key Facts document.
For information about your rights as a consumer visit Citizens Advice.

Our insurance comparison service is free and easy for you to use, but you are responsible for making sure all your information is entered correctly, and for choosing your insurer.

This site uses cookies in order to work correctly - these are not harmful and do not contain personal information. By using this site you consent to this. I understand  Tell me more

please wait ...